US will do its best to end Covid, says White House about IP rights waiver

Biden administration engaged in steps to increase vaccine production, says official.

Topics
Coronavirus Vaccine | intellectual property

Press Trust of India  |  Washington 

Vaccine, Moderna
A US trade representative has held meetings with CEOs of several vaccine manufacturing companies, including Moderna.

Ahead of a World Trade Organization meeting in Geneva next week to discuss a waiver of certain provisions of the Trade-Related Aspects of Rights (TRIPS) for COVID-19, the White House said it will do whatever is best to end the pandemic.

"We're going to do what's in the best interest of ending the pandemic. We are already engaged in steps to increase vaccine production," White House Deputy Press Secretary Karine Jean-Pierre told reporters aboard Air Force One on Thursday.

"Moderna announced that it will not enforce its COVID-19-related patents against those making vaccines intended to combat the pandemic. We recently secured a new partnership between Sanofi and Moderna to manufacture 200 million doses," she said.

Responding to a question, Jean-Pierre said no option is off the table and the guiding principle of the Biden administration is getting safe vaccines fast.

US Trade Representative Katherine Tai has held meetings with CEOs of several vaccine manufacturing companies, including Moderna and Pfizer, on the TRIPS waiver issue.

A day earlier, senators Elizabeth Warren, Edward J Markey, Tammy Baldwin, Jeffrey A Merkley, and Christopher Murphy wrote a letter to major vaccine producers as well.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Fri, April 30 2021. 05:44 IST
RECOMMENDED FOR YOU